OverviewSuggest Edit

ViewRay, Inc. designs, manufactures, and markets the MRIdian radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. The Company believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients.
TypePublic
Founded2004
HQOakwood Village, US
Websiteviewray.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Dec 2018)221(+59%)
Job Openings6
Revenue (FY, 2019)$87.8 M(+9%)
Share Price (Nov 2020)$3.7
Cybersecurity ratingFMore

Key People/Management at ViewRay

Scott Drake

Scott Drake

Chief Executive Officer, President
Shahriar (Shar

Shahriar (Shar

Chief Operating Officer
Stephen Strunk

Stephen Strunk

Vice President of Manufacturing
James F. Dempsey

James F. Dempsey

Chief Scientific Officer
Rob Fuchs

Rob Fuchs

Chief Human Resources Officer
Robert McCormack

Robert McCormack

Senior Vice President, General Counsel and Corporate Secretary
Show more

ViewRay Office Locations

ViewRay has offices in Oakwood Village and Mountain View
Oakwood Village, US (HQ)
2 Thermo Fisher Way
Mountain View, US
800 W El Camino Real
Mountain View, US
815 E Middlefield Rd
Oakwood Village, US
2 Thermo Fisher Way
Show all (4)

ViewRay Financials and Metrics

ViewRay Revenue

ViewRay's revenue was reported to be $87.78 m in FY, 2019
USD

Revenue (Q3, 2020)

10.1m

Gross profit (Q3, 2020)

(1.1m)

Gross profit margin (Q3, 2020), %

(10.5%)

Net income (Q3, 2020)

(28.1m)

EBIT (Q3, 2020)

(25.0m)

Market capitalization (20-Nov-2020)

555.4m

Closing stock price (20-Nov-2020)

3.7

Cash (30-Sept-2020)

163.9m

EV

458.3m
ViewRay's current market capitalization is $555.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.4m22.2m34.0m81.0m87.8m

Revenue growth, %

62%114%

Cost of goods sold

14.5m25.9m27.7m74.4m93.3m

Gross profit

(4.2m)(3.6m)6.3m6.6m(5.5m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

5.3m5.5m299.0k357.0k1.2m698.0k12.2m26.2m16.4m17.7m20.3m30.2m20.9m14.3m14.2m10.1m

Cost of goods sold

6.1m6.5m863.0k1.2m1.0m826.0k10.2m20.6m16.4m17.3m25.6m26.9m20.3m16.4m15.3m11.2m

Gross profit

(775.0k)(1.1m)(564.0k)(826.0k)185.0k(128.0k)2.0m5.6m69.0k364.0k(5.4m)3.2m574.0k(2.1m)(1.0m)(1.1m)

Gross profit Margin, %

(15%)(20%)(189%)(231%)15%(18%)16%21%0%2%(26%)11%3%(15%)(7%)(11%)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

11.1m20.7m14.2m57.4m167.4m226.8m

Accounts Receivable

904.0k830.0k4.2m20.3m36.9m16.8m

Prepaid Expenses

4.9m6.0m3.3m

Inventories

8.2m8.1m8.1m19.4m49.5m55.0m
Quarterly
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(33.8m)(45.0m)(50.6m)(72.2m)(76.4m)(120.2m)

Depreciation and Amortization

1.0m1.3m1.7m2.2m3.5m4.7m

Inventories

(703.0k)(1.7m)(12.3m)(32.2m)(6.0m)

Accounts Payable

(2.1m)381.0k6.3m(870.0k)2.8m
USDQ2, 2014

Financial Leverage

-1.1 x
Show all financial metrics

ViewRay Operating Metrics

ViewRay's Backlog was reported to be 133.2m in FY, 2016.
FY, 2016

Backlog

133.20 m

Patents (Foreign)

31

Patents (US)

19

Patents Pending

108
Show all operating metrics

ViewRay Revenue Breakdown

Embed Graph

ViewRay revenue breakdown by geographic segment: 24.7% from Netherlands, 22.9% from Italy, 46.7% from Japan and 5.8% from Other

ViewRay Cybersecurity Score

Cybersecurity ratingPremium dataset

F

58/100

SecurityScorecard logo

ViewRay Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

ViewRay Online and Social Media Presence

Embed Graph

ViewRay News and Updates

ViewRay Reports Third Quarter 2020 Results

CLEVELAND, Nov. 5, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights: Total revenue of $10.1 million, primarily from one revenue unit, compared to $20.9 million,...

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Pilgrim’s Pride Corporation, Resideo Technologies, Spirit Aerosystems, and ViewRay and Encourages Investors to Contact the Firm

NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Pilgrim’s Pride Corporation (NASDAQ: PPC), Resideo Technologies, Inc. (NYSE: REZI), Spirit AeroSystems Holdings, Inc.…

ViewRay, GenesisCare and the University of Oxford Announce Groundbreaking Compassionate Access Programme Now Open to UK Patients with Localized Pancreatic Cancer

CLEVELAND, Aug. 27, 2020 /PRNewswire/ --– ViewRay, Inc. (Nasdaq: VRAY) announced today that the GenesisCare Foundation's Compassionate Access Programme is now accepting patients for treatment on the MRIdian® MRI-Guided Radiation Therapy System. The program, in collaboration with the...

ViewRay Announces Conference Call for First Quarter 2020 Financial Results to be Held After Market on April 30, 2020

CLEVELAND, April 9, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2020 financial results. ViewRay will hold a conference call to discuss results on Thursday, April 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in...

ROSEN, A TOP RANKED LAW FIRM, Reminds ViewRay, Inc. Investors of Important Deadline in Securities Class Action

NEW YORK, Oct. 24, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ViewRay, Inc. from March 15, 2019 through August 8, 2019, inclusive (the "Class Period") of the important November 12, 2019 lead plaintiff deadline in the...

VIEWRAY SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In ViewRay, Inc. To Contact The Firm

NEW YORK, NY - (NewMediaWire) - October 04, 2019 -  -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in ViewRay, Inc. (“ViewRay” or the “Company”) (NASDAQ: VRAY) of the November 12, 2019 deadline to seek the role of lead plaintiff in a federal securities cl…
Show more

ViewRay Blogs

ASTRO 2020 to Feature Latest MRIdian Clinical Experience Highlighting Outcomes in Tough to Treat Cancer

Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions CLEVELAND , Oct. 21, 2020 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac MRI-guided radiation therapy system will be featured at the 2020 Annual Meeting of the

ViewRay Announces Conference Call for Third Quarter 2020 Financial Results to be Held After Market on November 5, 2020

ViewRay Announces Conference Call for Third Quarter 2020 Financial Results to be Held After Market on November 5, 2020 Content Import Thu, 10/15/2020 - 08:02 ViewRay Announces Conference Call for Third Quarter 2020 Financial Results to be Held After Market on November 5, 2020 …

ViewRay to Host Physician-led Webinar for Investors and Analysts at the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting

ViewRay to Host Physician-led Webinar for Investors and Analysts at the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting Content Import Thu, 10/01/2020 - 08:31 ViewRay to Host Physician-led Webinar for Investors and Analysts at the 2020 American Society of Radiation Oncol…

ViewRay Reports Second Quarter 2020 Results

CLEVELAND , July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020 .     Second Quarter 2020 Highlights: Total revenue of $14.2 million , primarily from two revenue units, compared to $30.2 million , primarily from

ViewRay Announces Conference Call for Second Quarter 2020 Financial Results to be Held After Market on July 30, 2020

ViewRay Announces Conference Call for Second Quarter 2020 Financial Results to be Held After Market on July 30, 2020 Content Import Mon, 07/13/2020 - 08:02 ViewRay Announces Conference Call for Second Quarter 2020 Financial Results to be Held After Market on July 30, 2020 07…

ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers

ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers Content Import Tue, 06/23/2020 - 08:01 ViewRay Announces 1-Year Outcomes on MR-Guided Radiation Treatment for Prostate Cancer Without Implanted Markers 06/23/20 …
Show more

ViewRay Frequently Asked Questions

  • When was ViewRay founded?

    ViewRay was founded in 2004.

  • Who are ViewRay key executives?

    ViewRay's key executives are Scott Drake, Shahriar (Shar and Stephen Strunk.

  • How many employees does ViewRay have?

    ViewRay has 221 employees.

  • What is ViewRay revenue?

    Latest ViewRay annual revenue is $87.8 m.

  • What is ViewRay revenue per employee?

    Latest ViewRay revenue per employee is $397.2 k.

  • Who are ViewRay competitors?

    Competitors of ViewRay include Accuray, NxStage Medical and ResMed.

  • Where is ViewRay headquarters?

    ViewRay headquarters is located at 2 Thermo Fisher Way, Oakwood Village.

  • Where are ViewRay offices?

    ViewRay has offices in Oakwood Village and Mountain View.

  • How many offices does ViewRay have?

    ViewRay has 4 offices.